Financial Data and Key Metrics Changes - The company reported normalized funds from operation (FFO) of $0.46 per diluted share for Q4 2025 and $1.72 per diluted share for the full year 2025, representing a 22% year-over-year growth in FFO per share compared to 2024 [21] - Total portfolio same-store NOI growth was 11.8% in Q4 and 14.2% for the full year 2025, marking the second consecutive year of double-digit growth [10][21] - The company improved its debt to EBITDA by nearly a full turn in 2025, entering 2026 with a net debt to EBITDA ratio of 3.4 times [21][24] Business Line Data and Key Metrics Changes - The operating portfolio, including Trilogy and SHOP segments, contributed 76.9% of consolidated cash NOI, with Trilogy's same-store NOI increasing 14% in Q4 and 18.4% for the full year [11][12] - SHOP segment same-store NOI increased 24.6% in Q4 and 25.2% for the full year 2025, with occupancy surpassing 90% [13] - The company expects continued strong performance in both Trilogy and SHOP segments, with guidance for 2026 indicating 8%-12% growth in Trilogy and 15%-19% growth in SHOP [23] Market Data and Key Metrics Changes - The company closed over $950 million in new investments in 2025, primarily in the SHOP segment, which is now the second-largest in terms of cash NOI [16] - The investment pipeline includes approximately $230 million in awarded deals, with ongoing deal activity expected to increase in 2026 [19][56] - The company anticipates that competitive pressure in its markets will remain muted due to historically low levels of new supply growth [18] Company Strategy and Development Direction - The company maintains a disciplined investment and capital allocation strategy focused on high-quality care and superior health outcomes [7][8] - The strategy includes a shift towards higher acuity assets and relationship-driven sourcing for acquisitions [16][64] - The company is focused on expanding its Trilogy segment and campus growth initiatives, leveraging existing assets to mitigate market risks [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering another year of double-digit same-store NOI growth in 2026, supported by strong occupancy levels and pricing discipline [12][23] - The leadership emphasized the importance of high-quality care and health outcomes, which are expected to drive demand in the aging population [13][18] - Management acknowledged the challenges in the operating environment but remains optimistic about the company's ability to navigate these challenges and capitalize on growth opportunities [24] Other Important Information - The company has a robust pipeline of acquisitions and is prepared to deploy capital competitively in response to increasing deal activity [19][56] - The management team is committed to maintaining operational alignment and clarity of execution during the leadership transition [6][9] Q&A Session Summary Question: Can you dive deeper into the acquisition environment? - Management noted a focus on higher acuity SHOP assets, indicating confidence in long-term stability for this asset class [27] Question: Can you discuss the guidance for SHOP and potential deceleration? - Management highlighted a significant increase in occupancy in 2025 and indicated that pricing power would increase as occupancy rises [32][34] Question: What are the expectations for the investment pipeline and yields? - Management indicated that they are seeing cap rate compression and are focused on acquiring higher quality properties [63] Question: How does the revenue management system rollout progress? - Management explained that the revenue management system is being piloted with select operators, aiming to enhance performance across the portfolio [46][51] Question: What is the outlook for Trilogy investments? - Management acknowledged increased competition but emphasized their advantage in off-market acquisitions and strong relationships with operators [80][82]

Healthcare Realty Trust (NYSE:HR) Q4 2025 Earnings call February 13, 2026 09:00 AM ET Company ParticipantsDan Gabbay - CFOMichael Carroll - Managing DirectorMichael Gorman - Managing Director of REITsNick Joseph - Head of US Real Estate and Lodging Research TeamNick Yulico - Managing DirectorOmotayo Okusanya - Managing Director and Head of US REIT ResearchPeter Scott - President and CEORob Hull - COORon Hubbard - VP of Investor RelationsRyan Crowley - CIOConference Call ParticipantsAustin Wurschmidt - Direc ...

Financial Data and Key Metrics Changes - The company reported normalized FFO per share of $1.61 for the full year 2025, exceeding the midpoint of original guidance by $0.03 [10] - Same-store NOI growth was 4.8%, surpassing the midpoint of original guidance by 140 basis points [11] - In Q4 2025, normalized FFO per share was $0.40, with same-store cash NOI growth of 5.5% [23] Business Line Data and Key Metrics Changes - The company executed approximately 5.8 million square feet of leases in 2025, including 1.6 million square feet of new leases [15] - Tenant retention improved to 82% for the year, with same-store absorption translating to over 100 basis points of occupancy gain [15][16] - Cash leasing spreads improved by 60 basis points, and tenant retention increased by 220 basis points under the new asset management platform [8] Market Data and Key Metrics Changes - The outpatient medical transaction volume increased significantly in 2025, driven by rising patient and tenant demand alongside a lack of new supply [11] - Demand in the top 100 MSAs continues to outstrip supply, with completions as a percentage of inventory remaining near all-time lows [16] Company Strategy and Development Direction - The company aims to become the leader in the outpatient medical sector, focusing on driving long-term shareholder value through a three-year strategic plan [5][6] - Key initiatives include revamping the asset management platform, achieving G&A savings, and executing an ambitious asset disposition plan [7][8] - The company has successfully sold $1.2 billion of assets at a blended cap rate of 6.7%, exceeding expectations [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's premier outpatient medical portfolio, supported by nearly 5% same-store NOI growth in 2025 [9] - The outlook for 2026 includes normalized FFO guidance of $1.58-$1.64 per share, with same-store cash NOI growth expected to be 3.5%-4.5% [25] - Management acknowledged the need for disciplined capital allocation due to current cost of capital and discount to intrinsic asset value [11] Other Important Information - The company has reduced net debt to EBITDA to 5.4 times, improving financial flexibility and liquidity [9] - The dividend has been right-sized to be appropriate and well-covered, currently offering a nearly 6% yield [10] Q&A Session Summary Question: Same-store NOI guidance for 2026 - Management explained that the 3.5%-4.5% guidance reflects expectations for escalators, retention, absorption, and cash leasing spreads, with a focus on pushing these metrics [31][32] Question: CapEx relative to FAD for 2026 - Management indicated that if FFO is flat, FAD is also expected to be flat, with maintenance capital numbers provided in guidance [36][38] Question: Absorption potential and redevelopment leasing - Management confirmed that the absorption figures discussed were for the same-store pool, with expectations for significant contributions from redevelopment projects [40][42] Question: Acquisition potential and profile - Management stated that any acquisitions would be pursued only if they meet yield expectations, emphasizing discipline in capital allocation [44][46] Question: Dispositions going forward - Management outlined a plan for $175 million in sales for the year, with some deals expected to close early in 2026 [49][50]

Core Viewpoint - Goldman Sachs initiated coverage of Healthpeak Properties Inc. with a Neutral rating and a price target of $17, highlighting improving occupancy and cash flow visibility in senior housing investments [1] Group 1: Company Overview - Healthpeak Properties Inc. operates as a fully integrated healthcare REIT, focusing on acquiring, developing, owning, leasing, and managing healthcare real estate across the United States [4] Group 2: Recent Developments - Healthpeak's portfolio has significantly changed since 2019, particularly due to the merger with Physicians Realty Trust, which closed on March 1, 2024, effectively doubling the size of its outpatient medical portfolio [2] - On January 7, Healthpeak announced plans to form and take public Janus Living, Inc., a new REIT focused entirely on senior housing, contributing its 34-community, 10,422-unit senior housing portfolio to Janus Living [3]

Core Viewpoint - Omega Healthcare Investors, Inc. is set to release its earnings results for the quarter ended December 31, 2025, on February 4, 2026, after market close [1] Earnings Release Details - The earnings results will be announced on February 4, 2026, after market close [1] - A conference call to discuss the fourth quarter results and current developments will take place on February 5, 2026, at 10 a.m. Eastern Time [1] - Investors and interested parties will have access to the conference call [1]

Core Viewpoint - Ventas (VTR) has experienced a significant stock price increase of 16.3% year-to-date, outperforming the industry growth of 4.4% [1][8] Company Overview - Ventas possesses a diverse portfolio of healthcare real estate assets in key markets in the U.S. and the U.K., positioning it to benefit from favorable industry fundamentals [2] - The senior housing operating portfolio (SHOP) is expected to gain from the aging population and increased healthcare spending by seniors [2] - The outpatient medical portfolio is anticipated to benefit from positive trends in outpatient visits [2] Financial Performance - The company has seen a 13.3% year-over-year growth in same-store cash NOI within the SHOP portfolio for Q2 2025 [5][8] - As of Q2 2025, Ventas reported liquidity of $4.7 billion, with net debt to EBITDA improving to 5.6X [8][10] - The Zacks Consensus Estimate for Ventas' 2025 FFO per share has been slightly revised upward to $3.46 over the past two months [3] Strategic Initiatives - Ventas is actively rebalancing its portfolio, which is expected to drive future revenue growth [3] - The company has expanded its operator base from 10 to 36 since December 2020, enhancing its growth potential in high-demand markets [5] - A disciplined capital-recycling strategy is in place, allowing the company to dispose of non-core assets and reinvest in premium acquisitions [9] Market Trends - The senior citizen population is projected to increase, providing a multi-year growth opportunity in senior housing [4] - The healthcare sector is relatively insulated from macroeconomic uncertainties, offering stability during economic downturns [4] - The growing population aged 65 and above is contributing to an increase in outpatient visits, which the outpatient medical and research (OM&R) portfolio is well-positioned to capitalize on [6]

Core Viewpoint - Ventas, Inc. (VTR) reported strong first-quarter 2025 results, with normalized funds from operations (FFO) per share of 84 cents, exceeding estimates and reflecting a 7.7% year-over-year increase [1][3] Financial Performance - VTR achieved revenues of $1.36 billion in Q1 2025, surpassing the Zacks Consensus Estimate of $1.30 billion and marking a 13.2% year-over-year growth [2] - Same-store cash net operating income (NOI) for the total property portfolio increased 7.1% to $485.4 million compared to the prior year [3] - The same-store cash NOI for the Senior Housing Operating Portfolio (SHOP) rose 13.6% year over year to $220.5 million, supported by a 3.8% growth in revenues per occupied room [4] Segment Performance - The outpatient medical and research portfolio's same-store cash NOI improved 1.3% year over year to $137.3 million, driven by higher average rent and revenue per occupied square foot [5] - The triple-net leased portfolio's same-store cash NOI increased 3.2% year over year to $127.6 million [5] Balance Sheet Position - At the end of Q1 2025, VTR had cash and cash equivalents of $182.3 million, down from $897.9 million at the end of 2024, with total liquidity of $2.9 billion [6] 2025 Guidance - VTR reaffirmed its 2025 normalized FFO per share guidance of $3.35-$3.46, with a midpoint of $3.41, and expects total same-store cash NOI growth between 5.5% and 8% [7] - The SHOP segment's same-store cash NOI is projected to grow between 11% and 16%, while the outpatient medical and research portfolio's same-store cash NOI is expected to be in the range of 2-3% [8]

Financial Performance & Portfolio Composition - The company's pro-rata annualized cash NOI totaled $413.912 million, with ISHC contributing 58.8%, OM 19.7%, SHOP 12.2%, Triple-Net Leased Properties 7.3%, and Debt Security Investment 2.0%[10] - Same-store ISHC revenues increased by 9.1% from Q4 2023 to $284.646 million in Q4 2024, and 7.8% from FY 2023 to $1.094 billion in FY 2024[15] - Same-store SHOP revenues increased by 11.5% from Q4 2023 to $44.793 million in Q4 2024, and 11.8% from FY 2023 to $174.310 million in FY 2024[26] - Same-store Triple-Net Leased Properties revenues increased by 1.0% from Q4 2023 to $7.597 million in Q4 2024, and 2.8% from FY 2023 to $30.583 million in FY 2024[31] Outpatient Medical (OM) - OM properties' ending occupancy was 87.9% as of December 31, 2024[20] - Same-store OM revenues increased by 2.1% from Q4 2023 to $31.960 million in Q4 2024, and 0.7% from FY 2023 to $127.722 million in FY 2024[20] Debt and Lease Expirations - Debt maturities and principal payments total $1.685 billion, with a weighted average interest rate of 4.42%[39] - In 2025, $14.576 million (13.4%) of OM ABR and $4.011 million (100%) of interest income are expiring[36] 2025 Guidance - The company anticipates total portfolio same-store NOI growth of 7.0% - 10.0% in FY 2025[45]